{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:23:59Z","timestamp":1761841439054},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T00:00:00Z","timestamp":1302825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s00417-011-1678-9","type":"journal-article","created":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T10:51:56Z","timestamp":1302778316000},"page":"1295-1301","source":"Crossref","is-referenced-by-count":13,"title":["Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series"],"prefix":"10.1007","volume":"249","author":[{"given":"Ramak","family":"Roohipoor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamed","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariba","family":"Ghassemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Karkhaneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Riazi-Esfahani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Nili-Ahmadabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,15]]},"reference":[{"key":"1678_CR1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0140-6736(97)01107-0","volume":"350","author":"C Gilbert","year":"1997","unstructured":"Gilbert C, Rahi J, Eckstein M, O\u2019Sullivan J, Foster A (1997) Retinopathy of prematurity in middle-income countries. Lancet 350:12\u201314","journal-title":"Lancet"},{"key":"1678_CR2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1091-8531(99)70091-1","volume":"3","author":"PG Steinkuller","year":"1999","unstructured":"Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK (1999) Childhood blindness. J AAPOS 3:26\u201332","journal-title":"J AAPOS"},{"key":"1678_CR3","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archopht.1984.01040030908011","volume":"102","author":"The Committee for the Classification of Retinopathy of Prematurity","year":"1984","unstructured":"The Committee for the Classification of Retinopathy of Prematurity (1984) An international classification of retinopathy of prematurity. Arch Ophthalmol 102:1130\u20131134","journal-title":"Arch Ophthalmol"},{"key":"1678_CR4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","volume":"106","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1988","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Arch Ophthalmol 106:471\u2013479","journal-title":"Arch Ophthalmol"},{"key":"1678_CR5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/archopht.124.1.24","volume":"124","author":"MX Repka","year":"2006","unstructured":"Repka MX, Tung BMS, Good W (2006) Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP). Arch Ophthalmol 124:24\u201330","journal-title":"Arch Ophthalmol"},{"key":"1678_CR6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archopht.1996.01100140287005","volume":"114","author":"WS Gilbert","year":"1996","unstructured":"Gilbert WS, Quinn GE, Dobson V, Reynolds J, Hardy RJ, Palmer EA, Multicenter Trial of Cryotherapy for Retinopathy of Prematurity Cooperative Group (1996) Partial retinal detachment at 3\u00a0months after threshold retinopathy of prematurity: long-term structural and functional outcome. Arch Ophthalmol 114:1085\u20131091","journal-title":"Arch Ophthalmol"},{"key":"1678_CR7","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1097\/IAE.0b013e318158ea0e","volume":"28","author":"WC Wu","year":"2008","unstructured":"Wu WC, Drenser KA, Lai M, Capone A, Trese MT (2008) Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity. Retina 28:S75\u2013S80","journal-title":"Retina"},{"key":"1678_CR8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","volume":"10","author":"J Chen","year":"2007","unstructured":"Chen J, Smith LE (2007) Retinopathy of prematurity. Angiogenesis 10:133\u2013140","journal-title":"Angiogenesis"},{"key":"1678_CR9","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.92.3.905","volume":"92","author":"EA Pierce","year":"1995","unstructured":"Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE (1995) Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92:905\u2013909","journal-title":"Proc Natl Acad Sci USA"},{"key":"1678_CR10","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480\u20131487","journal-title":"N Engl J Med"},{"key":"1678_CR11","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archopht.1996.01100140419009","volume":"114","author":"EA Pierce","year":"1996","unstructured":"Pierce EA, Foley ED, Smith LE (1996) Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 114:1219\u20131228","journal-title":"Arch Ophthalmol"},{"key":"1678_CR12","first-page":"281","volume":"151","author":"N Okamoto","year":"1997","unstructured":"Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, Zack DJ, Campochiaro PA (1997) Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151:281\u2013291","journal-title":"Am J Pathol"},{"key":"1678_CR13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.exer.2004.07.006","volume":"79","author":"XQ Werdich","year":"2004","unstructured":"Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS (2004) Variable oxygen and retinal VEGF levels: correlation with incidence with and severity of pathology in a rat model of oxygen-induced retinopathy. Exp Eye Res 79:623\u2013630","journal-title":"Exp Eye Res"},{"key":"1678_CR14","first-page":"290","volume":"37","author":"J Stone","year":"1996","unstructured":"Stone J, Chan-Ling T, Pe'er J, Itin A, Gnessin H, Keshet E (1996) Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 37:290\u2013299","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1678_CR15","first-page":"43","volume":"10","author":"DA Leske","year":"2004","unstructured":"Leske DA, Wu J, Fautsch MP, Karger RA, Berdahl JP, Lanier WL, Holmes JM (2004) The role of VEGF and IGF-1 in a hypercarbic oxygen-induced retinopathy rat model of ROP. Mol Vis 10:43\u201350","journal-title":"Mol Vis"},{"key":"1678_CR16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275\u2013278","journal-title":"Retina"},{"key":"1678_CR17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363\u2013372","journal-title":"Ophthalmology"},{"key":"1678_CR18","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity (2005) The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 123:991\u2013999","journal-title":"Arch Ophthalmol"},{"key":"1678_CR19","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684\u20131694","journal-title":"Arch Ophthalmol"},{"key":"1678_CR20","first-page":"311e25","volume":"25","author":"RJ Hardy","year":"2004","unstructured":"Hardy RJ, Good WV, Dobson V, Palmer EA, Phelps DL, Quintos M, Tung B, Early Treatment for Retinopathy of Prematurity Cooperative Group (2004) Multicenter trial of early treatment for retinopathy of prematurity: study design. Control Clin Trials 25:311e25","journal-title":"Control Clin Trials"},{"key":"1678_CR21","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","volume":"245","author":"EJ Eun Jee Chung","year":"2007","unstructured":"Eun Jee Chung EJ, Kim JH, Ahn HS, Koh HJ (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin\u00ae) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:1727\u20131730","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1678_CR22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/archopht.1990.01070040047029","volume":"108","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1990","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group (1990) Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Arch Ophthalmol 108:195\u2013204","journal-title":"Arch Ophthalmol"},{"key":"1678_CR23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ajo.2006.02.018","volume":"142","author":"JT Flynn","year":"2006","unstructured":"Flynn JT, Chan-Ling T (2006) Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease. Am J Ophthalmol 142:46\u201359","journal-title":"Am J Ophthalmol"},{"key":"1678_CR24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1067\/mpa.2000.107904","volume":"4","author":"X Katz","year":"2000","unstructured":"Katz X, Kychenthal A, Dorta P (2000) Zone I retinopathy of prematurity. J AAPOS 4:373\u2013376","journal-title":"J AAPOS"},{"key":"1678_CR25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1395-3907.2003.00171.x","volume":"81","author":"M O\u2019Keefe","year":"2003","unstructured":"O\u2019Keefe M, Lanigan B, Long VW (2003) Outcome of zone I retinopathy of prematurity. Acta Ophthalmol Scand 81:614\u2013616","journal-title":"Acta Ophthalmol Scand"},{"key":"1678_CR26","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","volume":"26","author":"A Kychenthal","year":"2006","unstructured":"Kychenthal A, Dorta P, Katz X (2006) Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina 26:S11\u2013S15","journal-title":"Retina"},{"key":"1678_CR27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1542\/peds.105.2.295","volume":"105","author":"The STOP-ROP Multicenter Study Group","year":"2000","unstructured":"The STOP-ROP Multicenter Study Group (2000) Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 105:295\u2013310","journal-title":"Pediatrics"},{"key":"1678_CR28","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1167\/iovs.05-1046","volume":"47","author":"HD Modanlou","year":"2006","unstructured":"Modanlou HD, Gharraee Z, Hasan J, Waltzman J, Nageotte S, Beharry KD (2006) Ontogeny of VEGF, IGF-I, and GH in neonatal rat serum, vitreous fluid, and retina from birth to weaning. Invest Ophthalmol Vis Sci 47:738\u2013744","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1678_CR29","first-page":"225","volume":"103","author":"BT Smith","year":"2005","unstructured":"Smith BT, Tasman WS (2005) Retinopathy of prematurity: late complications in the baby boomer generation (1946\u20131964). Trans Am Ophthalmol Soc 103:225\u2013236","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1678_CR30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3928\/0191-3913-20070301-10","volume":"44","author":"E McLoone","year":"2007","unstructured":"McLoone E, O\u2019Keefe M, Lanigan B (2007) Effect of diode laser ablative therapy for threshold retinopathy of prematurity on the visual field: results of Goldmann perimetry at a mean age of 11\u00a0years. J Pediatr Ophthalmol Strabismus 44:170\u2013173","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"1678_CR31","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RRJR (2008) Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28:831\u2013838","journal-title":"Retina"},{"key":"1678_CR32","first-page":"532","volume":"12","author":"GA Lutty","year":"2006","unstructured":"Lutty GA, Chan-Ling T, Phelps DL, Adamis AP, Berns KI, Chan CK, Cole CH, D'Amore PA, Das A, Deng WT, Dobson V, Flynn JT, Friedlander M, Fulton A, Good WV, Grant MB, Hansen R, Hauswirth WW, Hardy RJ, Hinton DR, Hughes S, McLeod DS, Palmer EA, Patz A, Penn JS, Raisler BJ, Repka MX, Saint-Geniez M, Shaw LC, Shima DT, Smith BT, Smith LE, Tahija SG, Tasman W, Trese MT (2006) Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis 12:532\u2013580","journal-title":"Mol Vis"},{"key":"1678_CR33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.iae.0000233327.68433.02","volume":"26","author":"PM Beer","year":"2006","unstructured":"Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S (2006) Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26:871\u2013876","journal-title":"Retina"},{"key":"1678_CR34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/archopht.118.5.645","volume":"118","author":"MX Repka","year":"2000","unstructured":"Repka MX, Palmer EA, Tung B (2000) Involution of retinopathy of prematurity. Arch Ophthalmol 118:645\u2013649","journal-title":"Arch Ophthalmol"},{"key":"1678_CR35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","volume":"38","author":"A Travassos","year":"2007","unstructured":"Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE, Prieto I, Pires G, van Velze R, Valido A, Machado Mdo C (2007) Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 38:233\u2013237","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"1678_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00417-008-0952-y","volume":"247","author":"JS Schouten","year":"2009","unstructured":"Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F (2009) A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 247:1\u201311","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1678_CR37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","volume":"14","author":"JC Law","year":"2010","unstructured":"Law JC, Recchia FM, Morrison DG, Donahue SP, Estes RL (2010) Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 14:6\u201310","journal-title":"J AAPOS"},{"key":"1678_CR38","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.1523\/JNEUROSCI.20-18-06781.2000","volume":"15","author":"PA Yourey","year":"2000","unstructured":"Yourey PA, Gohari S, Su JL, Alderson RF (2000) Vascular endothelial cell growth factors promote the in vitro development of rat photoreceptor cells. J Neurosci 15:6781\u20136788","journal-title":"J Neurosci"},{"key":"1678_CR39","first-page":"68","volume":"74","author":"T Murata","year":"1996","unstructured":"Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K (1996) The temporal and spatial vascular endothelial growth factor expression in retinal vasculogenesis of rat neonates. Lab Invest 74:68\u201379","journal-title":"Lab Invest"},{"key":"1678_CR40","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855\u2013859","journal-title":"Ophthalmology"},{"key":"1678_CR41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jaapos.2009.06.003","volume":"13","author":"RL Avery","year":"2009","unstructured":"Avery RL (2009) Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern. J AAPOS 13:329\u2013331","journal-title":"J AAPOS"},{"key":"1678_CR42","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1167\/iovs.09-4425","volume":"51","author":"WC Wu","year":"2010","unstructured":"Wu WC, Lai CC, Chen KJ, Chen TL, Wang NK, Hwang YS, Yeung L, Li LM (2010) Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes. Invest Ophthalmol Vis Sci 51:3701\u20133708","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1678_CR43","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","volume":"248","author":"JY Lee","year":"2010","unstructured":"Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG (2010) Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 248:1257\u20131262","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1678_CR44","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","volume":"90","author":"AE Fung","year":"2006","unstructured":"Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol 90:1344\u20131349","journal-title":"Br J Ophthalmol"},{"key":"1678_CR45","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","volume":"28","author":"H Quiroz-Mercado","year":"2008","unstructured":"Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV (2008) Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 28:S19\u2013S25","journal-title":"Retina"},{"key":"1678_CR46","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","volume":"245","author":"EJ Chung","year":"2007","unstructured":"Chung EJ, Kim JH, Ahn HS, Koh HJ (2007) Combination of laser photocoagulation and intravitreal bevacizumab for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:1727\u20131730","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1678_CR47","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","volume":"28","author":"GA Lalwani","year":"2008","unstructured":"Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, Johnson RA, Puliafito CA (2008) Off-label use of intravitreal bevacizumab (avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28:S13\u2013S18","journal-title":"Retina"},{"key":"1678_CR48","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0002-9394(03)00190-9","volume":"136","author":"KA Hutcheson","year":"2003","unstructured":"Hutcheson KA, Nguyen ATQ, Preslan MW, Ellish NJ, Steidl SM (2003) Vitreous hemorrhage in patients with high-risk retinopathy of prematurity. Am J Ophthalmol 136:258\u2013263","journal-title":"Am J Ophthalmol"},{"key":"1678_CR49","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/IAE.0b013e31817f2f15","volume":"28","author":"MJ Kim","year":"2008","unstructured":"Kim MJ, Kim S, Yu YS (2008) The risk for retinal detachment associated with hemorrhages pre and postlaser treatment in retinopathy of prematurity. Retina 28:1451\u20131457","journal-title":"Retina"},{"key":"1678_CR50","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0002-9394(14)71402-3","volume":"116","author":"A Capone Jr","year":"1993","unstructured":"Capone A Jr, Diaz-Rohena R, Sternberg P, Mandell B, Lambert HM, Lopez PF (1993) Diode-laser photocoagulation for zone 1 threshold retinopathy of prematurity. Am J Ophthalmol 116:444\u2013450","journal-title":"Am J Ophthalmol"},{"key":"1678_CR51","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ajo.2004.12.106","volume":"140","author":"DK Coats","year":"2005","unstructured":"Coats DK, Miller AM, Hussein MA, McCreery KM, Holz E, Paysse EA (2005) Involution of retinopathy of prematurity after laser treatment: factors associated with development of retinal detachment. Am J Ophthalmol 140:214\u2013222","journal-title":"Am J Ophthalmol"},{"key":"1678_CR52","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3928\/01913913-20080301-09","volume":"45","author":"CL Funnell","year":"2008","unstructured":"Funnell CL, Simmons IG (2008) Retinopathy of prematurity treatment and vitreous hemorrhage. J Pediatr Ophthalmol Strabismus 45:118\u2013120","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"1678_CR53","first-page":"281","volume":"103","author":"DK Coats","year":"2005","unstructured":"Coats DK (2005) Retinopathy of prematurity involution, factors predisposing to retinal detachment, and expected utility of preemptive surgical intervention. Trans Am Ophthalmol Soc 103:281\u2013312","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1678_CR54","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.ophtha.2009.07.001","volume":"116","author":"H Ahmadieh","year":"2009","unstructured":"Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R (2009) Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 116:1943\u20131948","journal-title":"Ophthalmology"},{"key":"1678_CR55","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-011-1678-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-011-1678-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-011-1678-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T07:07:47Z","timestamp":1592464067000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-011-1678-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,15]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["1678"],"URL":"https:\/\/doi.org\/10.1007\/s00417-011-1678-9","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,15]]}}}